| Literature DB >> 20040092 |
Nathan J Bowen1, L DeEtte Walker, Lilya V Matyunina, Sanjay Logani, Kimberly A Totten, Benedict B Benigno, John F McDonald.
Abstract
BACKGROUND: Accumulating evidence suggests that somatic stem cells undergo mutagenic transformation into cancer initiating cells. The serous subtype of ovarian adenocarcinoma in humans has been hypothesized to arise from at least two possible classes of progenitor cells: the ovarian surface epithelia (OSE) and/or an as yet undefined class of progenitor cells residing in the distal end of the fallopian tube.Entities:
Mesh:
Year: 2009 PMID: 20040092 PMCID: PMC2806370 DOI: 10.1186/1755-8794-2-71
Source DB: PubMed Journal: BMC Med Genomics ISSN: 1755-8794 Impact factor: 3.063
Patient Samples Analyzed in this Study
| OCI # | AGE AT TIME OF SURGERY | TISSUE FOR MICROARRAY | HISTOPATHOLOGY OF TUMOR OR SURFACE EPITHELIUM | STAGE | GRADE | INDICATION FOR REMOVAL OF HEALTHY OVARIES | MENOPAUSE STATUS |
|---|---|---|---|---|---|---|---|
| 317 | 59 | CEPI | serous adenocarcinoma | Ic | 3 | N/A | postmenopausal |
| 336 | 63 | CEPI | serous adenocarcinoma | Ic | 3 | N/A | postmenopausal |
| 367 | 56 | CEPI | serous adenocarcinoma | II | 3 | N/A | postmenopausal |
| 242 | 63 | CEPI | serous adenocarcinoma | IIb | 3 | N/A | postmenopausal |
| 183 | 66 | CEPI | serous adenocarcinoma | III | 2 | N/A | postmenopausal |
| 413 | 49 | CEPI | serous adenocarcinoma | III | 3 | N/A | postmenopausal |
| 229 | 58 | CEPI | serous adenocarcinoma | IIIc | 3 | N/A | postmenopausal |
| 369 | 52 | CEPI | serous adenocarcinoma | IIIc | 2 | N/A | postmenopausal |
| 528 | 66 | CEPI | serous adenocarcinoma | IIIc | 3 | N/A | postmenopausal |
| 588 | 71 | CEPI | serous adenocarcinoma | IIIc | 2/3 | N/A | postmenopausal |
| 489 | 48 | CEPI | serous adenocarcinoma | IIIc-IV | 3 | N/A | perimenopausal |
| 542 | 61 | CEPI | serous adenocarcinoma | IV | 3 | N/A | postmenopausal |
| 434 | 41 | OSE | WNL | N/A | N/A | atypical complex hyperplasia in polypoid endometrium | perimenopausal |
| 437 | 54 | OSE | WNL | N/A | N/A | cervical adenocarcinoma | postmenopausal |
| 440 | 50 | OSE | WNL | N/A | N/A | uterine myoma | perimenopausal |
| 448 | 63 | OSE | WNL | N/A | N/A | uterine myoma | postmenopausal |
| 452 | 51 | OSE | WNL | N/A | N/A | endometrial adenocarcinoma | perimenopausal |
| 463 | 48 | OSE | WNL | N/A | N/A | endometrial adenocarcinoma | perimenopausal |
| 470 | 44 | OSE | WNL | N/A | N/A | endometrial adenocarcinoma | premenopausal |
| 475 | 63 | OSE | WNL | N/A | N/A | benign simple cyst in right ovary; left ovary brushing used for microarray | postmenopausal |
| 541 | 41 | OSE | WNL | N/A | N/A | adenomyosis uteri and endometriosis | perimenopausal |
| 552 | 41 | OSE | WNL | N/A | N/A | prophylactic TAH-BSO, previous breast and vulval cancer and family history | premenopausal |
| 563 | 66 | OSE | WNL | N/A | N/A | endometrial adenocarcinoma | postmenopausal |
| 567 | 77 | OSE | WNL | N/A | N/A | endocervical adenocarcinoma | postmenopausal |
Abbreviations: CEPI - cancer epithelia; OSE - ovarian surface epithelia; WNL - within normal limits; LMP - last menstrual period; HYST - hysterectomy;
TAH-BSO - total abdominal hysterectomy with bilateral salpingo-oopherectomy
Figure 1Hierarchical clustering and gene ontology (GO) enrichment of 2320 genes differentially expressed between ovarian surface epithelial cells and ovarian cancer epithelial tissue. The heat map (left) was generated by Z-score normalization of log2 expression values from Affymetrix HGU133 Plus 2.0 3. Displayed are the relative expression levels of genes (rows) differentially expressed (red = relatively over-expressed; green = relatively under-expressed) in 12 ovarian surface epithelial brushings and 12 laser capture microdissected malignant epithelia samples (columns). Unique, enriched GO terms are listed for each set of differentially expressed genes and their statistical significance by false discovery rate (FDR) corrected, hypergeometric distribution p-values. Genes overexpressed in CEPI are labeled as CEPI Genes overexpressed in OSE are labeled OSE Genes.
Figure 2Cell cycle pathway gene expression. Shown is a GenMAPP http://www.genmapp.org rendering of a modified KEGG (Kyoto Encyclopedia of Genes and Genomes, http://www.genome.jp/kegg/) schematic of cell cycle pathway genes. Genes significantly overexpressed in CEPI relative to OSE are colored red. The execution of the cell cycle is depicted from left to right and individual phases identified below by I- beam brackets. Genes involved in maintaining G1 are generally under-expressed in CEPI while genes involved in G1 to S progression, G2, and M are over-expressed.
Figure 3Pathway deregulation in ovarian cancer. Individual signaling pathways hypothesized to be deregulated in the oncogenic transformation of ovarian surface epithelia (OSE) into ovarian cancer epithelia (CEPI). An individual OSE is represented on the left with individual pathways (as discussed in the text) labeled adjacent to their respective section of each cell. An individual CEPI with the same signaling pathways is represented on the right as a mirror image of the OSE cell. The legend describes the colored boxes and lines used to represent expression differences and potential interactions among genes. The juxtapositional placement of the two cell halves is meant to emphasize the dichotomous state of signaling between the OSE and CEPI as revealed by our gene expression microarrays.
Figure 4Immunohistochemistry of OSE gene products. Immunohistochemistry was performed on fresh frozen paraffin embedded OSE and CEPI tissue samples. Staining with primary antibodies against (A) secreted frizzled-related protein 1 (SFRP1), (B) aldehyde dehydrogenase 1 family, member A2 (ALDH1A2), and (C and D) lim homeobox 9 (LXH9) indicated strong protein expression in OSE (labeled arrow) and lower or absent protein expression in CEPI (labeled arrow), consistent with mRNA expression values shown in Additional file 5. Each image is a typical representative from 10 normal and 10 cancer slides. The slides chosen for display contain both CEPI and normal adjacent OSE from the same tissue sample.